The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Activity Overview

Antibody-drug conjugates (ADCs) are rapidly transforming the therapeutic landscape of metastatic breast cancer (MBC), reshaping treatment selection and sequencing across multiple disease subtypes. Agents targeting HER2 and TROP2 have demonstrated clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) across HER2-positive, HER2-low/ultralow, and triple-negative breast cancer populations. Recent pivotal trials, along with updated NCCN guideline recommendations, are expanding the role of ADCs into earlier lines of therapy and in combination with immunotherapy. As a result, clinicians must increasingly navigate complex decisions regarding patient selection, optimal sequencing of multiple ADCs, management of unique toxicity profiles, and integration of emerging ADC-based strategies with established endocrine, targeted, and HER2-directed therapies.

In this program, expert-led presentations will contextualize emerging clinical trial data and guideline updates. At the same time, interactive case discussions will allow faculty to explore real-world decision-making challenges related to ADC selection, sequencing, toxicity management, and treatment personalization in MBC.

This educational activity is an archive of the live virtual symposium held during the 25th Annual International Congress on the Future of Breast Cancer^® East on July 10, 2026.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists, along with fellows, advanced practice professionals, nurses, pharmacists, and other health care practitioners who manage breast cancer in their patients.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Analyze recent clinical trial evidence for TROP2- and HER2-directed antibody-drug conjugates (ADCs) to inform treatment decision-making in metastatic breast cancer
• Integrate patient, biomarker, and disease characteristics when determining the sequencing of TROP2- and HER2-directed ADC therapies
• Implement evidence-based strategies to monitor and manage adverse events associated with HER2- and TROP2-directed ADC therapies

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.